

Juan Luis Steegmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6127871/publications.pdf>

Version: 2024-02-01

58
papers

513
citations

759233

12
h-index

713466

21
g-index

59
all docs

59
docs citations

59
times ranked

879
citing authors

#	ARTICLE	IF	CITATIONS
1	Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study. <i>Leukemia and Lymphoma</i> , 2021, 62, 739-742.	1.3	3
2	Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection. <i>Biochemical Pharmacology</i> , 2020, 182, 114203.	4.4	9
3	Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1217-1224.	2.8	5
4	Cutaneous side effects in a cohort of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: General description and further characterization, correlation with photoexposure and study of hypopigmentation as treatment's prognostic factor. <i>Dermatologic Therapy</i> , 2020, 33, e14428.	1.7	4
5	Immediate Effects of Dasatinib on the Migration and Redistribution of Na ⁺ ve and Memory Lymphocytes Associated With Lymphocytosis in Chronic Myeloid Leukemia Patients. <i>Frontiers in Pharmacology</i> , 2019, 10, 1340.	3.5	11
6	Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2019, 98, 321-330.	1.8	21
7	Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors. <i>Biochemical Pharmacology</i> , 2018, 156, 248-264.	4.4	14
8	Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?. <i>Annals of Hematology</i> , 2018, 97, 2089-2098.	1.8	18
9	Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients. <i>Blood</i> , 2018, 132, 47-47.	1.4	1
10	Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. <i>Haematologica</i> , 2017, 102, 103-109.	3.5	52
11	An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2059-2066.	2.5	6
12	Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1585-1596.	2.5	29
13	Dasatinib Reversibly Disrupts Endothelial Vascular Integrity by Increasing Non-Muscle Myosin II Contractility in a ROCK-Dependent Manner. <i>Clinical Cancer Research</i> , 2017, 23, 6697-6707.	7.0	41
14	PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase. <i>PLoS ONE</i> , 2017, 12, e0181366.	2.5	8
15	ENESTPath: A Phase 3 Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with Imatinib: 24-Month Analysis of the First 300 Patients in the Induction/Consolidation Phase. <i>Blood</i> , 2016, 128, 3094-3094.	1.4	11
16	Safety and Efficacy of Dasatinib Treatment Change for Patients Previously Treated with Imatinib with Late Warning Response. Results from the Phase II, Open, Multicenter Dasapost Study. <i>Blood</i> , 2016, 128, 5450-5450.	1.4	1
17	The Molecular Response at 3 Months, Measured Using a Genxpert Platform, Predicts Further Outcomes in Chronic Myeloid Patients, but the Cutoff Differs from the 10% Cutoff Commonly Used with the EUTOS Method. <i>Blood</i> , 2016, 128, 1906-1906.	1.4	0
18	Real Life Long-Term Survival Analysis in Patients with Chronic Myeloid Leukemia Treated with Tkis in Spain. <i>Blood</i> , 2016, 128, 3074-3074.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program. American Journal of Hematology, 2015, 90, 429-433.	4.1	19
20	ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single-Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy. Blood, 2015, 126, 138-138.	1.4	22
21	Molecular Response at 3 Months Measured with Genexpert BCR-ABL (IS) Platform Predicts Further Outcome in Chronic Myeloid Patients but the Cutoff Differs from the 10% Commonly Used with BCR-ABL (IS) EUTOS Method. Blood, 2015, 126, 2776-2776.	1.4	1
22	Enestpath: A Phase III Study to Assess the Effect of Nilotinib Treatment Duration on Treatment-Free Remission (TFR) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) Patients (pts) Previously Treated with Imatinib: Interim Analysis from the First Year of Induction Phase. Blood, 2015, 126, 4040-4040.	1.4	7
23	Impact of Age on Efficacy and Toxicity of Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis. Blood, 2015, 126, 479-479.	1.4	1
24	The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia. Blood, 2015, 126, 595-595.	1.4	3
25	Measurement of PTCH1 Expression at Diagnosis Is an Appropriate Tool for Tyrosine Kinase Inhibitors Selection in Chronic Myeloid Leukemia Patients in Chronic Phase. Blood, 2015, 126, 2791-2791.	1.4	0
26	Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients. Blood, 2015, 126, 2786-2786.	1.4	0
27	Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis. Blood, 2015, 126, 4054-4054.	1.4	0
28	Efficacy and Safety of Dasatinib in Late Suboptimal Response CML Patients a Its Relation with Lymphocytosis, Lymphocyte Migration and Chemokine Receptor Expression. Blood, 2015, 126, 4015-4015.	1.4	0
29	Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?. American Journal of Hematology, 2014, 89, E206-11.	4.1	6
30	Baseline Characteristics of CML Patients Across Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials. Blood, 2014, 124, 3160-3160.	1.4	2
31	Bosutinib Appears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program. Blood, 2014, 124, 5523-5523.	1.4	3
32	Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data. Blood, 2014, 124, 3145-3145.	1.4	2
33	Peripheral Arterial Occlusive Disease (PAOD) In Patients (Pts) Receiving Dasatinib: Experience Across Multiple Clinical Trials. Blood, 2013, 122, 1489-1489.	1.4	8
34	CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry. Blood, 2013, 122, 2735-2735.	1.4	1
35	Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study. Blood, 2013, 122, 4030-4030.	1.4	3
36	Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd.. Journal of Clinical Oncology, 2013, 31, 7054-7054.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up.. Journal of Clinical Oncology, 2013, 31, 7053-7053.	1.6	0
38	NK-Cells In Dasatinib-Treated Chronic Myeloid Leukemia Patients Display a Unique Phenotype Associated With Cytotoxic Potential. Blood, 2013, 122, 1475-1475.	1.4	0
39	Very Early Molecular Responses During The First Two Months Of Therapy Are Highly Predictive Of Deep Molecular Responses In Newly-Diagnosed Chronic Myeloid Leukemia In Chronic Phase(CML-CP) Patients Treated Upfront With Nilotinib. The Spanish Substudy Of The ENEST1st Trial. Blood, 2013, 122, 5190-5190.	1.4	0
40	Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leukemia and Lymphoma, 2012, 53, 2351-2361.	1.3	90
41	Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data. Blood, 2012, 120, 1675-1675.	1.4	18
42	EUTOS Score Is Also Valid in CML Patients Not Involved in Clinical Studies. Blood, 2012, 120, 3759-3759.	1.4	2
43	Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.. Journal of Clinical Oncology, 2012, 30, 6506-6506.	1.6	15
44	Outcomes of Chronic Myeloid Leukemia (CML) Patients Who Stopped Second Generation Tyrosine Kinase Inhibitors (2GTKIs) As Second Line Treatment. Results of the CML Spanish National Registry (RELMC). Blood, 2012, 120, 3764-3764.	1.4	8
45	A Good Adherence to ELN 09 Recommendations in Chronic Myeloid Leukemia (CML) Treatment with Imatinib, Is Associated with Better Outcomes in Patients Treated Outside Clinical Trials. Blood, 2012, 120, 3762-3762.	1.4	0
46	Switching to a Second Generation TKI in Chronic Myeloid Leukemia Patients with Late Suboptimal Response with Imatinib Obtained Better Molecular Responses That the "Watch and Wait" Approach. an Experience of a Multicenter Registry in Patients Outside Clinical Trials. Blood, 2012, 120, 3768-3768.	1.4	1
47	Effect of Time to Dasatinib Initiation On Outcome of Imatinib-Intolerant Patients with Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Results From a European Observational Study (FORTE;) Tj ETQq1 1 0.7843 14 rgB5/Overlook	1.4	0
48	Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry. Blood, 2011, 118, 1688-1688.	1.4	0
49	Survival and Response Outcomes to Different Treatment Schedules in CML Patients Starting Therapy with Imatinib. Results from the CML Spanish Registry (RELMC). Blood, 2010, 116, 1237-1237.	1.4	0
50	Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response.. Blood, 2009, 114, 1121-1121.	1.4	0
51	The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry.. Blood, 2009, 114, 4272-4272.	1.4	11
52	Newly acquired chromosome Abnormalities During Course of CLL: a Retrospective Collection Data From 2 Spanish Centers.. Blood, 2009, 114, 4384-4384.	1.4	0
53	Transforming and Tumorigenic Activity of JAK2 by Fusion to BCR: Molecular Mechanisms of Action of a Novel BCR-JAK2 Tyrosin-Kinase.. Blood, 2009, 114, 4683-4683.	1.4	0
54	Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy. Blood, 2008, 112, 573-573.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia. <i>Haematologica</i> , 2003, 88, 762-8.	3.5	36
56	Severe autoimmune hepatitis in a chronic myeloid leukemia patient treated with interferon alpha and with complete genetic response. , 1998, 59, 95-97.		13
57	Treatment of Chronic Myeloid Leukemia Relapsing After Allogeneic Bone Marrow Transplantation: The Case for Giving Interferon. <i>Blood</i> , 1998, 91, 2617-2619.	1.4	1
58	Treatment of Chronic Myeloid Leukemia Relapsing After Allogeneic Bone Marrow Transplantation: The Case for Giving Interferon. <i>Blood</i> , 1998, 91, 2617-2619.	1.4	0